Roche's Vemurafenib Filed With Companion Diagnostic In Tow
This article was originally published in The Pink Sheet Daily
Executive Summary
Roche/Genentech seeks priority review and broad indication in metastatic melanoma for ground-breaking BRAF inhibitor.